Format

Send to

Choose Destination
J Gastrointest Oncol. 2014 Feb;5(1):E1-6. doi: 10.3978/j.issn.2078-6891.2013.038.

Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6.

Author information

1
Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid Avenue St. Louis Missouri 63110, USA.

Abstract

Small bowel adenocarcinoma is an uncommon gastrointestinal malignancy with limited data on effective chemotherapy in the adjuvant setting, as well as for advanced disease. We present a case report of a patient with recurrent duodenal adenocarcinoma after resection and adjuvant chemotherapy who experienced a complete response to bevacizumab with oxaliplatin and 5FU (FOLFOX) followed by bevacizumab/capecitabine maintenance therapy for 2 years. The patient continues to be disease-free 8 years after his recurrence. This case highlights the potential of vascular endothelial growth factor (VEGF) inhibitors to enhance chemotherapeutic regimens for advanced small bowel adenocarcinoma.

KEYWORDS:

Small bowel adenocarcinoma; bevacizumab; capecitabine; oxaliplatin

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center